Werewolf Therapeutics, Inc. - HOWL Company Short-Term Debt

werewolftx.com (HOWL) - corporate logo

Is it worth investing in Werewolf Therapeutics (HOWL), whose management aims to create a safe cytokine cancer therapy? Monitoring short-term liabilities provides the answer, where the current mark equals 0.00. Stability is ensured by the independent synthesis of components for supply chains. Meanwhile, its status as a biotech startup allows the company to focus on patent protection for innovative treatments against solid tumors, avoiding direct operational competition.

HOWL: Werewolf Short-Term Debt 07/04/2022 - 10/28/2026

HOWL (Werewolf Therapeutics Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Werewolf|HOWL - Average Forecast Price
- market capitalization data:
Market Value Werewolf Therapeutics, Inc.|HOWL - Total Company Value
- book capitalization data:
Net Assets per Single Share Werewolf Therapeutics|HOWL - Total Stockholders' Equity|Market Capitalization to Book Value Ratio werewolftx.com|HOWL - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio Werewolf Therapeutics|HOWL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Werewolf|HOWL - Aggregate Debt Obligations|Debts to Book Capitalization Werewolf Therapeutics, Inc.|HOWL - Long-Term Debt Volume|Company Short-Term Debt Werewolf Therapeutics
Analysis of all company metrics:werewolftx.com HOWL
Finished products of Werewolf Therapeutics

The stable legal status of Werewolf Therapeutics (HOWL) developments in the US minimizes external risks, creating a reliable foundation for operational activities. An analysis of short-term debt reflects the total volume of obligations maturing within twelve months, allowing for an assessment of liquidity and the issuer's ability to service urgent loans, which confirms the financial stability of the business within the biologics sector.

Competitor analysis for Werewolf Therapeutics

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|Innate Pharma - Company Short-Term Debts|PYXS (Pyxis Oncology) - Short-Term Debt Volume|Company Short-Term Debt CGEN|Company Current Liabilities IOBT|Company Short-Term Debt STRO (Sutro Biopharma, Inc.)|Company Current Liabilities minktherapeutics.com INKT|Company Current Liabilities IMMX (Immix Biopharma)|alxoncology.com - Company Short-Term Debts|Cue Biopharma (CUE) - Company Short-Term Debt|PDSB: Company Short-Term Indebtedness|Company Short-Term Debt SONN|Short-Term Debt MAIABiotech.com|Liminatus Pharma LLC - Company Current Liabilities|Short-Term Indebtedness Lava Tx (LVTX)|Company Current Liabilities NextCure Corp|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt